25.06.2013 • News

BP Wins Approval for new PTA Plant in China

China's National Development and Reform Commission (NDRC) has approved plans by BP Zhuhai, an 85:15 joint venture of the British oil and petrochemicals producer and China's Zhuhai Port, to build a new 1.25m t/y plant for polyester feedstock PTA at Zhuhai in Guangdong province. The new CNY 4.1bn (€500m) plant, called Zhuhai 3, is planned to go on stream in late 2014. France's Technip has the engineering contract.

Since announcing expansion plans for the Chinese site in early 2011, BP and its local partner have completed two additional projects, bringing total capacity at the site to over 2.7 million and the group's global output capability to 8.25 t. The fast-growing Chinese demand is driven mainly by the textile industry, BP said. PET polymerization accounts for at most 10%.

Nick Elmslie, CEO of BP Global Petrochemicals, said Zhuhai 3, which uses the group's newest proprietary technology, "should make the Chinese joint venture the most competitive PTA producer in the world." The technology being licensed for about a year, "should deliver a step change in environmental performance, reducing both greenhouse gas emissions and other waste streams significantly," added Mark Wilson, BP president of Aromatics Asia and China Olefins & Derivatives.

Compared with other commonly used technologies, the new BP plant is expected to discharge 75% less waste water and generate 95% less solid waste. It is also expected to achieve a 65% reduction in greenhouse gas emissions.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read